CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 52 filers reported holding CTI BIOPHARMA CORP in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $15,000 | -67.4% | 12,573 | -74.9% | 0.00% | – |
| Q1 2020 | $46,000 | -41.8% | 50,073 | 0.0% | 0.00% | – |
| Q4 2019 | $79,000 | +88.1% | 50,073 | 0.0% | 0.00% | – |
| Q3 2019 | $42,000 | -2.3% | 50,073 | 0.0% | 0.00% | – |
| Q2 2019 | $43,000 | -12.2% | 50,073 | 0.0% | 0.00% | – |
| Q1 2019 | $49,000 | +32.4% | 50,073 | 0.0% | 0.00% | – |
| Q4 2018 | $37,000 | -66.7% | 50,073 | -2.9% | 0.00% | – |
| Q3 2018 | $111,000 | -56.8% | 51,573 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $257,000 | +25.4% | 51,573 | -1.9% | 0.00% | 0.0% |
| Q1 2018 | $205,000 | +135.6% | 52,598 | +61.5% | 0.00% | – |
| Q4 2017 | $87,000 | -16.3% | 32,573 | 0.0% | 0.00% | – |
| Q3 2017 | $104,000 | +1055.6% | 32,573 | +1166.0% | 0.00% | – |
| Q2 2017 | $9,000 | -81.6% | 2,573 | -78.0% | 0.00% | – |
| Q1 2017 | $49,000 | – | 11,673 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 4,068,191 | $4,719,000 | 9.14% |
| CAXTON CORP | 619,460 | $719,000 | 0.76% |
| BVF INC/IL | 6,929,690 | $8,038,000 | 0.50% |
| NEA Management Company, LLC | 7,140,450 | $8,283,000 | 0.33% |
| Orbimed Advisors | 9,520,600 | $11,044,000 | 0.16% |
| Renaissance Technologies | 2,103,792 | $2,440,000 | 0.00% |
| Paloma Partners Management Co | 30,289 | $35,000 | 0.00% |
| WEDBUSH SECURITIES INC | 12,600 | $15,000 | 0.00% |
| HRT FINANCIAL LP | 19,710 | $22,000 | 0.00% |
| FIRST MANHATTAN CO. LLC. | 33 | $0 | 0.00% |